{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T13:38:59Z","timestamp":1776605939505,"version":"3.51.2"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011785","name":"Guangxi Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bmcl.2026.130570","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:15:23Z","timestamp":1770016523000},"page":"130570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel sophocarpine derivatives as potential dual Bcl-2 and Mcl-1 inhibitors: design, synthesis and anti-hepatocellular carcinoma evaluation"],"prefix":"10.1016","volume":"135","author":[{"given":"Die","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YongQuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130570_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmcl.2026.130570_bb0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2026.130570_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5114\/ceh.2021.109312","article-title":"Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma","volume":"7","author":"Rehman","year":"2021","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.bmcl.2026.130570_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2026.130570_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112530","article-title":"An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2026.130570_bb0030","article-title":"Molecular bases of drug resistance in hepatocellular carcinoma","volume":"12","author":"Marin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.bmcl.2026.130570_bb0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1440-1746.2010.06582.x","article-title":"Cell death and hepatocarcinogenesis: dysregulation of apoptosis signaling pathways","volume":"26","author":"Schattenberg","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bmcl.2026.130570_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.bmcl.2026.130570_bb0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.bmcl.2026.130570_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1242\/jcs.031682","article-title":"Control of mitochondrial apoptosis by the Bcl-2 family","volume":"122","author":"Brunelle","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bmcl.2026.130570_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Cang","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2026.130570_bb0060","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to Venetoclax in patients with progressive chronic lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmcl.2026.130570_bb0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","article-title":"Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL","volume":"36","author":"Seyfried","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bmcl.2026.130570_bb0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3324\/haematol.2023.284353","article-title":"LP-118 is a novel B-cell lymphoma 2 \/ extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia","volume":"110","author":"Ravikrishnan","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.bmcl.2026.130570_bb0075","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2026.130570_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1353234","article-title":"A review on the pharmacology, pharmacokinetics and toxicity of sophocarpine","volume":"15","author":"Wei","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130570_bb0085","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1742-7843.2010.00653.x","article-title":"In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens ait","volume":"108","author":"Lin","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.bmcl.2026.130570_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2016.01.011","article-title":"Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT\/GSK-3beta\/beta-catenin axis and TGF-beta induced EMT with sophocarpine","volume":"376","author":"Zhang","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmcl.2026.130570_bb0095","doi-asserted-by":"crossref","first-page":"15686","DOI":"10.1038\/s41598-018-33908-8","article-title":"Synthesis, characterization and in vitro biological evaluation of two matrine derivatives","volume":"8","author":"Cheng","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2026.130570_bb0100","first-page":"737","article-title":"Mitochondria-mediated apoptosis in mammals. Protein","volume":"5","author":"Xiong","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2026.130570_bb0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2144\/000113610","article-title":"Mitochondrial membrane potential probes and the proton gradient: a practical usage guide","volume":"50","author":"Perry","year":"2011","journal-title":"Biotechniques"},{"key":"10.1016\/j.bmcl.2026.130570_bb0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bmcl.2011.12.023","article-title":"Induction of microtubule-damage, mitotic arrest, Bcl-2 phosphorylation, Bak activation, and mitochondria-dependent caspase cascade is involved in human Jurkat T-cell apoptosis by aruncin B from Aruncus dioicus var. kamtschaticus","volume":"22","author":"Han","year":"2012","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:47:15Z","timestamp":1776602835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"alternative-id":["S0960894X26000375"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130570","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel sophocarpine derivatives as potential dual Bcl-2 and Mcl-1 inhibitors: design, synthesis and anti-hepatocellular carcinoma evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130570"}}